Another potential coronavirus vaccine is moving along, with especially good news for the elderly. "While further testing is ongoing on thousands of volunteers, these initial findings are encouraging and demonstrate that clear progress is being made in the search for a safe and effective vaccine", said Dr al-Khal. That's a standout response considering COVID-19 tends to be more severe in older patients.
A vaccine that works is seen as a game-changer in the battle against the novel coronavirus, which has killed more than 1.15 million people, shuttered swathes of the global economy and turned normal life upside down for billions of people.
The second phase of Oxford-AstraZeneca's experimental COVID-19 vaccine trials has been completed and the Brihanmumbai Municipal Corporation (BMC) will soon start the third phase of its clinical trials in Mumbai, Hindustan Times has reported. This vaccine is expected to protect people from the coronavirus for about a year.
Researchers looked whether the vaccine accurately follows the genetic instructions programmed into it by the Oxford team, providing clarity on how it provokes an immune response. Even healthcare workers would be recruited for the trial, he said.
Blood tests carried out on a set of older participants reflect data released in July which showed the vaccine did generate "robust immune responses" in healthy adults aged 18 to 55.
AstraZeneca has signed several supply and manufacturing deals with companies and governments around the world as it gets closer to reporting early results of a late-stage clinical trial.
More than 200 vaccine candidates are now in development globally.
The Hyderabad-based vaccine maker had applied to the Drugs Controller General of India (DCGI) on October 2, seeking permission to conduct Phase 3 trials.
It resumed the United States trial of the experimental vaccine after approval by USA regulators, the company said on Friday.
Wilder-Smith said there is a possibility that several vaccines could be rolled out simultaneously.